Publicaciones en colaboración con investigadores/as de Universidad de Medellín (1)

2018

  1. The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial

    Clinical and Experimental Immunology, Vol. 191, Núm. 2, pp. 229-239